Tetracaine hydrochloride (CAS 136-47-0, C₁₅H₂₄N₂O₂·HCl, molecular weight 300.82 g/mol) is an ester-type local anesthetic whose injectable veterinary use concentrates around regional nerve blocks, epidural administration, and short-duration diagnostic procedures. The API is dissolved in water for injection to produce solutions of 0.2%, 0.5%, 1.0%, or 2.0% w/v. The pH is adjusted with dilute hydrochloric acid or sodium hydroxide to a target range of pH 4.5–5.5. This range maintains the hydrochloride salt in solution while limiting hydroxide-ion-catalysed ester hydrolysis. Tonicity is adjusted with sodium chloride to 290–310 mOsm/kg. Terminal sterilisation is not recommended because the ester bond is susceptible to hydrolytic degradation under moist heat. Instead, the solution is passed through a 0.22 μm PVDF or PES membrane filter under aseptic conditions. Pre-filtration through a 0.45 μm polypropylene depth filter is necessary when the bulk solution shows visible particulate or when raw API has a high bioburden. Production-scale filling lines for tetracaine hydrochloride injectables typically use Type I glass vials with butyl rubber stoppers. Peristaltic pump tubing made from silicone may sorb the lipophilic free base if the pH rises above 6.0; platinum-cured silicone or polyethylene-lined tubing is preferred. Vessels and hold tanks should be stainless steel or glass-lined because exposure to uncoated aluminium can accelerate discolouration. The resulting solution must meet sterility under USP <71>, bacterial endotoxin under USP <85>, and particulate matter limits under USP <788>. In equine lameness diagnostic nerve blocks, the slower onset of tetracaine compared to lidocaine must be reflected in the block-to-evaluation interval. Accidental intravascular injection carries a higher systemic toxicity risk than lidocaine because of the drug's cardiotoxic potential; aspiration before injection and slow injection technique are mandatory.

Why Does Terminal Heat Sterilization Fail for Tetracaine Hydrochloride Solutions?

Terminal heat sterilisation subjects tetracaine hydrochloride to both high temperature and the presence of water, which drives ester hydrolysis to 4-(butylamino)benzoic acid and 2-(dimethylamino)ethanol. The degradation is strongly pH dependent. At pH values above 6.0, hydroxide-ion catalysis accelerates hydrolysis. At pH values below 2.0, acid-catalysed hydrolysis can also occur, although the hydrochloride salt remains dissolved. The most stable aqueous pH window for the unformulated API is approximately pH 4.0–5.0 at ambient storage. Steam sterilisation at 121 °C for 15 min may reduce assay potency unpredictably depending on buffer species, dissolved oxygen, and container headspace; published degradation rate constants for every container configuration are limited. For this reason, aseptic processing is the standard manufacturing route for parenteral tetracaine hydrochloride solutions. Compounding is performed in an ISO Class 5 environment under unidirectional airflow as described by ISO 13408-1. The filtered solution is transferred through 0.22 μm membrane filters. Filter integrity is verified before and after use by bubble point or diffusive flow testing according to the filter manufacturer certificate. The maximum hold time between final filtration and filling should be validated for the specific solution, container, and closure system; batches held beyond the validated limit cannot be released. In-process pH measurement uses a calibrated pH meter with a low-sodium-error electrode. Dissolved oxygen is reduced by nitrogen sparging before filling where headspace oxygen exceeds 2.0%. The table below summarises the pH-dependent physical state and hydrolysis risk that governs whether a clear, stable solution can be manufactured and aseptically filled.

In ophthalmic preparations, tetracaine hydrochloride is compounded as a 0.5% aqueous solution for corneal anaesthesia in dogs, cats, and horses before tonometry, foreign body removal, or conjunctival scraping. The solution is buffered to pH 4.5–5.5 with acetate or boric acid buffers. Phosphate buffers are avoided because tetracaine free base can precipitate at higher pH and because inorganic phosphate may contribute to incompatibility with some preservative systems. Tonicity is adjusted to 290–310 mOsm/kg with sodium chloride or mannitol. Ophthalmic products must meet the requirements of USP <771> for ophthalmic preparations, sterility under USP <71>, and preservative efficacy under USP <51> when multidose containers are used. Benzalkonium chloride at 0.01% is a common preservative but can produce corneal epithelial toxicity with repeated application; therefore, preservative-free single-dose units are preferred for compromised corneas. Chlorobutanol at 0.5% is an alternative but is unstable above pH 5.0 and is not suitable for heat sterilisation. Light exposure promotes discolouration and degradation; solutions are filled into amber Type I glass bottles or opaque low-density polyethylene blow-fill-seal ampoules. Nitrogen flushing of the headspace to less than 2.0% residual oxygen reduces oxidative decomposition. On filling lines, product contact surfaces should be polypropylene, polyethylene, or 316L stainless steel. Repeated topical administration of tetracaine delays corneal epithelialization and should be avoided in deep corneal ulcers; published data for this specific veterinary indication are limited to short-duration diagnostic use.

When Tetracaine Hydrochloride Is Dry-Blended into Veterinary Powders and Granules

When tetracaine hydrochloride is processed as a dry powder for subsequent tablet compression, capsule filling, or premix dilution, the moisture content of the raw API must be checked before blending. The free-flowing crystalline powder is hygroscopic; storage in tight containers below 60% relative humidity is required. If the loss-on-drying value exceeds 0.5%, the powder may be vacuum-dried at 40 °C for a validated holding period before weighing. Geometric dilution with lactose monohydrate or mannitol is mandatory because the API is active at low mass fractions. Blending is performed in a V-blender or bin blender at 10–15 rpm for 10–20 min. Content uniformity of the blend is verified by sampling at multiple points per USP <905>. Particle size segregation can occur if the API has a very different particle size distribution from the diluent; the blend should be sieved through a 60-mesh (250 μm) or 80-mesh (180 μm) screen before final mixing. Wet granulation with water is unsuitable because tetracaine hydrochloride dissolves in the granulating fluid and migrates to the granule surface during drying, causing poor distribution and punch sticking during compression. Dry granulation by slugging or roller compaction is the preferred method when granulation is necessary. The table below summarises solubility ratios that inform solvent selection for any non-aqueous granulation or coating step. For direct compression, magnesium stearate is used at 0.5%–1.0% w/w as a lubricant; over-lubrication can delay tablet disintegration beyond the limit in USP <701>. Tablets intended for oral mucosal use are compressed to a hardness of 3–6 kp and a friability below 1.0% per USP <1216>. Tetracaine hydrochloride is not recognised as a feed premix drug in food-producing species; any extralabel use in such animals is subject to 21 CFR 530.4, and published withdrawal interval data for this specific configuration are limited.

Dental and Oromucosal Gel Formulation Parameters and Onset Kinetics

Dental and oromucosal gels containing tetracaine hydrochloride are compounded at 0.5%–2.0% w/w for gingival anaesthesia before scaling, extraction, or oral mass removal. The selection of the thickening polymer determines the pH environment around the API. Carbomer 934P requires neutralisation with triethanolamine or sodium hydroxide to reach gel viscosity; the resulting pH above 6.5 can precipitate tetracaine free base and reduce anaesthetic activity. Hydroxyethyl cellulose, hydroxypropyl methylcellulose, or sodium carboxymethyl cellulose are preferred because these polymers thicken without the need for a high-pH neutralisation step. The gel is prepared by dispersing the polymer in water or a water-propylene glycol mixture, hydrating under vacuum, and adding tetracaine hydrochloride as a concentrated aqueous stock solution at the end of the process. The pH is checked and adjusted to pH 4.5–5.5 using dilute hydrochloric acid. Viscosity is measured with a Brookfield rotational viscometer at 20 rpm and 25 °C; typical target values for a spreadable mucosal gel are 20,000–60,000 mPa·s, although published data for this specific API concentration are limited. In inflamed oral tissue the local pH is often 5.5–6.5, which increases the ionised fraction of tetracaine because its pKa is approximately 8.5; this reduces penetration into the nerve membrane and prolongs the onset compared with amide local anaesthetics. Vasodilatation can shorten the duration of action, but the addition of epinephrine to dental gels is generally avoided in small animal oral mucosa because of local ischaemia risk. Gels are filled into light-resistant tubes or single-dose syringes and stored below 25 °C.

Epidural and Subarachnoid Administration Demands Strict Density and pH Control

Epidural and subarachnoid administration of tetracaine hydrochloride in small ruminants, cattle, and swine requires preservative-free solutions because antimicrobial preservatives such as benzyl alcohol are neurotoxic when injected into the spinal space. The solution is prepared as a 1.0% or 2.0% tetracaine hydrochloride injection. Hyperbaric spinal solutions are produced by adding dextrose monohydrate to increase the density above cerebrospinal fluid; the final density is verified with an oscillating U-tube densitometer and is typically adjusted to 1.010–1.030 g/cm³. The pH is adjusted to pH 4.5–5.5 before final filtration. Aseptic filling into single-dose glass ampoules is required. The ampoules are flushed with nitrogen and sealed to prevent oxygen ingress. Because the cerebrospinal fluid is slightly alkaline at approximately pH 7.3, the acidic injection creates a temporary local pH shift; the onset of motor block is rapid when hyperbaric dispersion is used, but the duration varies by species and dose. Epidural use in food-producing animals must follow extralabel drug use restrictions under 21 CFR 530.4, and published withdrawal interval data for this specific configuration are limited. Each sterilised ampoule is inspected for leaks, particulates, and seal integrity. The final product must comply with USP <1> for injections, USP <788> for particulate matter, USP <85> for bacterial endotoxins, and USP <71> for sterility.

Direct compression of tetracaine hydrochloride into oral mucosal tablets requires geometric dilution of the active powder with a directly compressible diluent such as spray-dried lactose, mannitol, or microcrystalline cellulose. The blend is prepared by passing the API and diluent through a 40-mesh (425 μm) sieve before mixing. Content uniformity is tested per USP <905> on a minimum of 10 tablets. Tablet hardness for buccal or sublingual use is maintained at 3–6 kp to allow slow erosion without rapid disintegration; disintegration time is measured per USP <701> using water at 37 °C. Hard gelatin capsules may be used as compounding containers for powders intended for extemporaneous dissolution into oral rinses or topical solutions. Capsules are not intended for swallowed oral administration because tetracaine undergoes rapid plasma esterase hydrolysis and extensive first-pass metabolism, which limits systemic therapeutic utility. The powder-filled capsules should be stored in tight, light-resistant containers at 15–25 °C. For tablets, the lubricant magnesium stearate is used at 0.5%–1.0% w/w. Friability is controlled below 1.0% per USP <1216>. Water activity of the powder blend should remain below 0.60 to avoid caking and hydrolytic degradation. Batch-to-batch variance in stickiness during compression is reported when ambient relative humidity exceeds 60%; granulation and compression suites should be dehumidified below that threshold. Because oral mucosal contact is prolonged, the formulation should not include alkaline fillers such as calcium carbonate that would raise local pH above 6.0 and precipitate free base.